European for-profit radiotherapy internationalises
The European for-profit radiotherapy market now has five international consolidators, which we map out in this week’s infographic. What’s driving the trend?
This week, a Spanish listed group told us it is looking at acquiring single radiotherapy clinics having already entered the Spanish and Portuguese markets. Its CFO said it could bring know-how in helping centres still doing traditionally radiotherapy to move towards single-dose radiotherapy, also called hypofractionation.
The move to single-dose has been partially accelerated by the huge waiting lists caused by the COVID-19 pandemic, which opens up the possibility that more and more traditional centres may opt to become part of groups which can accelerate adoption. Atrys would be the third international group to go into the sector in France after MedEuropa and pan-European Amethyst Radiotherapy.
A second driver of the internationalisation of the sector may be the fact that radiotherapy is highly capital-intensive and highly-specialised. This makes a well-capitalised, specialist player the best-placed to succeed operationally.
See the market share of the companies in this infographic in our HBI Intelligence Oncology report.
We would welcome your thoughts on this story. Email your views to Cameron Murray or call 0207 183 3779.
